Launch Catch-Up — Agreement Extension Announced October 26, 2026
Regeneron said October 26 that it extended a federal supply agreement for Inmazeb, its three-antibody treatment for Ebola disease caused by Orthoebolavirus zairense.
The company expects to provide additional doses to the U.S. government through 2031 and receive approximately $270 million. The extension builds on a 2020 procurement agreement with the Biomedical Advanced Research and Development Authority, or BARDA, within the Department of Health and Human Services.
The announced value covers expected deliveries and payments over several years. It does not mean all doses have already been delivered or the full amount has been paid.
Inmazeb’s FDA approval dates to 2020. The supply extension is a preparedness procurement announcement, not a new drug approval.
Regeneron separately described research involving one antibody component against Bundibugyo virus. That investigational work is distinct from Inmazeb’s approved indication for Orthoebolavirus zairense; efficacy against other virus species has not been established for Inmazeb.
Sources Regeneron — October 26 agreement announcement: https://investor.regeneron.com/news-releases/news-release-details/regeneron-extends-agreement-barda-provide-additional-supply